Business
Result of GM
Result of GM.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 7632P Immupharma PLC 22 February 2016 \n\n 22 FEBRUARY 2016\nImmuPharma PLC\n \nResult of GM\n \nImmuPharma PLC (LSE:IMM) (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed.\nCommenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: \"We are delighted to have received such support from our existing shareholders and new investors in this placing to fund our pivotal Phase III Lupuzor™ trial. Having recently announced that we have commenced dosing our first Lupus patients in the US, we look forward to providing regular updates on the trial through this year and 2017.\"\n \nFor further information please see the Company's website, www.immupharma.org, or contact:\n\n\n\n\nImmuPharma plc\nTim McCarthy, Chairman\nLisa Baderoon, Head of Investor Relations\n \n \n\n\n+ 44 (0) 20 7152 4080\n \n+ 44 (0) 7721 413496\[email protected]\n\n\n\n\nPanmure Gordon (Financial Adviser, Nominated Adviser & Broker)\nFred Walsh, Duncan Monteith, Corporate Finance\nCharles Leigh-Pemberton, Corporate Broking\n \n\n\n+44 (0) 20 7886 2500\n\n\n\n\n \nAll defined terms used in this announcement are defined, unless otherwis...